Introgen`s INGN 241 Product Potentially Useful Gene Therapy for Human Melanoma
(PR Newswire)...INGN 241 is currently in Phase I clinical development for the treatment of solid tumors.......Introgen is also conducting a Phase II clinical trial for INGN 201 in lung cancer and Phase I trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer....- Mar 02 9:00 AM ET
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
Posted on: 03/02/2001
"Yahoo - Introgen's INGN 241 Product Potentially Useful Gene Therapy for Human Melanoma"
[ Latest Headlines
News Alerts ]
Friday March 2, 9:00 am Eastern Time
Introgen Therapeutics, Inc.
Introgen's INGN 241 Product Potentially Useful Gene Therapy for Human Melanoma
Study Results Announced at Fifth World Conference on Melanoma
VENICE, Italy, March 2 /PRNewswire/ --
Introgen Therapeutics, Inc. (Nasdaq: INGN - news) announced today that INGN 241
(adenoviral-mda7) has demonstrated antitumor activity against human melanoma
cells in vitro.
INGN 241 is currently in Phase I clinical development for the
treatment of solid tumors.
Elizabeth Grimm, Ph.D., Ashbel Smith Professor in
the Departments of Tumor Biology and Surgical Oncology at The University of
Texas M. D. Anderson Cancer Center, and principal investigator of the study,
presented these data at the Fifth World Conference on Melanoma, sponsored by
the World Health Organization.
The preclinical study showed that INGN 241 caused growth arrest and
induced apoptotic death in melanoma cells derived from both early and
metastatic stages of disease.
The anti-tumor effects were tumor-selective, as
INGN 241 did not kill normal melanocytes, the skin cell involved in melanoma
Melanoma is the most malignant of skin cancers.
In the United
States, the incidence of melanoma is increasing more rapidly than any other
Currently available therapies for advanced melanoma have an
approximately 80% failure rate and better therapies are needed.
"Gene therapy for melanoma using a gene originally isolated from growth-
arrested melanoma cells may provide a unique approach to treating melanoma,"
said Dr. Grimm.
"Adenoviral mda-7 is a broad spectrum anti-cancer agent and
uses growth control mechanisms that are different than other gene therapy
These studies also demonstrate that although different genes are
mutated in different tumor types, INGN 241 can re-establish fundamental growth
controls leading to induction of apoptosis in melanoma tumor cells."
The melanoma differentiation associated gene-7 (mda-7) was discovered by
Dr. Paul B. Fisher of Columbia University, who identified in preclinical
studies that mda-7 is up-regulated during melanoma differentiation.
has shown that INGN 241 (an adenoviral vector carrying the mda-7 gene) can
induce cell death or apoptosis in a broad range of cancer cells.
"Introgen has demonstrated in preclinical studies that INGN 241 has
activity against a wide variety of tumor types, including breast, lung and
colon cancer," said Sunil Chada, Ph.D, director of research and development
for Introgen. "Introgen's collaboration with Dr. Grimm provides new
opportunities to evaluate development of this drug in melanoma."
Introgen is a leader in the development and production of gene-based drugs
for the treatment of cancer and other diseases.
Introgen's product candidates
engage precise molecular targets to produce a highly specific therapeutic
By selectively killing cancer cells and harnessing natural protection
mechanisms, Introgen's product candidates may be less toxic than conventional
Introgen specializes in combining appropriate gene delivery
systems and therapeutic genes to make its gene-based drugs.
product candidate, INGN 201, is currently in Phase III clinical trials for the
treatment of head and neck cancer.
INGN 201 has been used in numerous
clinical trials worldwide either alone or in combination with conventional
treatments such as chemotherapy and radiotherapy.
Introgen is also conducting
a Phase II clinical trial for INGN 201 in lung cancer and Phase I trials for
INGN 201 in additional cancer indications including prostate, ovarian,
bladder, brain, and breast cancer. New applications using the human immune
system with INGN 201 are being explored.
Introgen's second product candidate,
INGN 241 (Adenoviral-mda7) for the treatment of solid tumors, is in Phase I
Certain statements in this press release that are not strictly historical
may be "forward-looking" statements, which involve risks and uncertainties.
Such forward-looking statements include, but are not limited to, those
relating to safety and efficacy of drug product candidates, specifically with
respect to melanoma cells.
There can be no assurance that Introgen will be
able to commercially develop gene-based drugs, that necessary regulatory
approvals will be obtained or that any clinical trials or studies undertaken
will be successful or that the proposed treatments will prove to be safe
The actual results may differ from those described in this
press release due to risks and uncertainties that exist in Introgen's
operations and business environment, including, but without limitation,
Introgen's stage of product development and the limited experience in the
development of gene-based drugs in general, its dependence upon proprietary
technology and current competition, history of operating losses and
accumulated deficits, Introgen's reliance on collaborative relationships, and
uncertainties related to clinical trials, safety, efficacy, the ability to
obtain the appropriate regulatory approvals, patent protection and market
acceptance, as well as other risks detailed from time to time in Introgen's
filings with the Securities and Exchange Commission, including its prospectus
dated October 12, 2000, filed with the Securities and Exchange Commission and
the 10-Q filed with the Securities and Exchange Commission on
February 14, 2001.
Introgen undertakes no obligation to publicly release the
results of any revisions to any forward-looking statements that reflect events
or circumstances arising from the date hereof.
C. Channing Burke of Introgen Therapeutics, Inc., 512-708-9310,
Ext. 322, or email@example.com; or Lora Pike of Noonan/Russo
Communications, 415-677-4455, Ext. 211, or firstname.lastname@example.org, for
Introgen Therapeutics, Inc.
Introgen Therapeutics, Inc.
Email this story - Most-emailed articles - Most-viewed articles
Copyright © 2001 Yahoo! Inc. All rights reserved.
Terms of Service
Copyright © 2001 PR
All rights reserved.
Republication or redistribution of PRNewswire content
is expressly prohibited
without the prior written consent of PRNewswire.
PRNewswire shall not be liable for any errors or delays
in the content,
or for any actions taken in reliance
Questions or Comments?
Click HERE to return to brain tumor news headlines